Ipsen Sells the North American1 Development and Marketing Rights for Apokyn® to Britannia Pharmaceuticals Limited, Achieving a Key Milestone in the Execution of its New North American Strategy
11/3/2011 6:20:55 AM
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that it has sold its North American1 development and marketing rights for Apokyn® indicated in the United States for the acute, intermittent treatment of hypomobility “off” episodes associated with advanced Parkinson’s disease to Britannia Pharmaceuticals. Ipsen will no longer record Apokyn® sales in its accounts from November 30th, 2011 onwards. For reference, 2010 sales of Apokyn® in the US amounted to $7.9 million (€6.0 million).
comments powered by